- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.0001 - Volume
5 - Avg. Volume
0 - Market Cap (intraday)
4,544 - Beta (5Y Monthly) 93.05
- PE Ratio (TTM)
-- - EPS (TTM)
-2.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Banyan Corp., through its subsidiaries, engages in the franchising of chiropractic clinics in North America. It provides practice development training and assistance to chiropractors, as well as offers franchise support and related services to franchisees and licensees. The company also offers diagnostic testing services. Banyan Corporation provides nerve conduction velocity (NCV) testing to patients through health care professionals, such as doctors and chiropractors. The NCV testing measures the transmission of nerve impulses through the body, identifies problems in the nervous system, and enables to substantiate the cost of treatment to patients and their insurers. In addition, it manufactures and markets the VT3000, a nerve testing system for the diagnosis of neuropathies, which are diseases of the peripheral nerves and parts of the spine, as well as nerve irritation and other damage to the nervous system of a patient. The company was founded in 1978 and is based in Beverly Hills, California.
20
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BNYN
View MorePerformance Overview: BNYN
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BNYN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BNYN
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-114.99%
Return on Assets (ttm)
-25.21%
Return on Equity (ttm)
--
Revenue (ttm)
3.48M
Net Income Avi to Common (ttm)
-4M
Diluted EPS (ttm)
-2.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
66.58k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
1.86M